Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter results for period ended September 30, 2026 announced.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced
- Business update included alongside financial results
- Detailed results and financial schedules available in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished for institutional investor and analyst meetings
- Presentation may contain updated corporate, pipeline or financial information relevant to AQST valuation
- Exhibit 99.2 and company investor-relations website provide the substantive disclosure
Item EX-99.1 · Exhibit EX-99.1
- Anaphylm NDA resubmission accepted as Class 2, with FDA PDUFA goal date March 16, 2027
- Potential first oral rescue treatment for anaphylaxis, creating meaningful commercial upside if approved
- Q3 revenue fell 41% to $7.6 million, primarily from timing of Suboxone orders
- Net loss widened to $16.5 million, while adjusted EBITDA loss increased to $12.2 million
- Cash $90.3 million at September 30, 2026, with unchanged 2026 revenue guidance of $46 million to $50 million
Item EX-99.2 · Exhibit EX-99.2
- Anaphylm NDA resubmitted in Q3 2026, with FDA PDUFA goal date March 16, 2027
- Commercial launch preparations remain on track, but revenue upside depends on FDA approval and market adoption
- Libervant out-licensing delivered $10 million upfront, with potential $47.5 million milestones and mid-teens net-sales royalties
- Ending cash declined to $90.3 million in Q3 2026, highlighting funding importance ahead of Anaphylm launch
- 2026 outlook: revenue approximately $46-$50 million and adjusted EBITDA loss approximately $35-$30 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.